- Home
- COCH vs FGEN Comparison
COCH vs FGEN Comparison
Compare COCH & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COCH
- FGEN
- Stock Information
- Founded
- COCH 1995
- FGEN 1993
- Country
- COCH United States
- FGEN United States
- Employees
- COCH N/A
- FGEN N/A
- Industry
- COCH Blank Checks
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- COCH Finance
- FGEN Health Care
- Exchange
- COCH Nasdaq
- FGEN Nasdaq
- Market Cap
- COCH 29.8M
- FGEN 34.5M
- IPO Year
- COCH N/A
- FGEN 2014
- Fundamental
- Price
- COCH $1.41
- FGEN $0.57
- Analyst Decision
- COCH Strong Buy
- FGEN
- Analyst Count
- COCH 3
- FGEN 0
- Target Price
- COCH $8.00
- FGEN N/A
- AVG Volume (30 Days)
- COCH 54.8K
- FGEN 1.7M
- Earning Date
- COCH 11-14-2024
- FGEN 02-24-2025
- Dividend Yield
- COCH N/A
- FGEN N/A
- EPS Growth
- COCH N/A
- FGEN N/A
- EPS
- COCH N/A
- FGEN N/A
- Revenue
- COCH $278,000.00
- FGEN $180,015,000.00
- Revenue This Year
- COCH N/A
- FGEN $22.05
- Revenue Next Year
- COCH $19.76
- FGEN N/A
- P/E Ratio
- COCH N/A
- FGEN N/A
- Revenue Growth
- COCH 15.35
- FGEN 16.15
- 52 Week Low
- COCH $1.08
- FGEN $0.18
- 52 Week High
- COCH $11.46
- FGEN $2.93
- Technical
- Relative Strength Index (RSI)
- COCH 38.92
- FGEN 57.36
- Support Level
- COCH $1.21
- FGEN $0.51
- Resistance Level
- COCH $1.50
- FGEN $0.76
- Average True Range (ATR)
- COCH 0.20
- FGEN 0.09
- MACD
- COCH 0.01
- FGEN -0.00
- Stochastic Oscillator
- COCH 32.26
- FGEN 33.26
About COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing innovative medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.